Swine Pseudorabies Vaccine Market Intelligence Report 2026 — Updated June 2026

Swine Pseudorabies Vaccine by Type (Swine Pseudorabies Vaccine , Live, Swine Pseudorabies　Vaccine, Inactivated, World Swine Pseudorabies Vaccine Production), by Application (Farms, Individual, World Swine Pseudorabies Vaccine Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Swine Pseudorabies Vaccine Market Overview

The Swine Pseudorabies Vaccine market encompasses immunization products—live attenuated, inactivated, and recombinant formulations—used to prevent and control Aujeszky’s disease in swine populations worldwide. Swine Pseudorabies Vaccine market size was estimated at USD 280 million in 2025, and industry analysts project a robust growth outlook with a CAGR of 5.2% for the 2026‑2033 market forecast, driven by rising pork consumption, stringent disease‑control regulations, and rapid vaccine‑technology innovation supporting broader industry expansion.

Loading chart…

Key forces shaping the market include the adoption of recombinant vaccine platforms that offer enhanced efficacy and safety, tightening governmental mandates that require routine pseudorabies immunization for herd certification, and consolidation among major pork producers that amplifies bulk purchasing power. The Asia‑Pacific region, led by China’s extensive swine industry, remains the largest market, while Latin America—particularly Brazil and Mexico—emerges as the fastest‑growing region, propelled by expanding pork demand and increasing investment in veterinary health infrastructure. These dynamics underscore a strategic opportunity for vaccine manufacturers to accelerate R&D pipelines and strengthen distribution networks to capture the projected market upside.

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	891.74 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Keqian Biology; Zybio; Jinyu Biology; Cahic; Pulike Biology; Hayao; Qilu Animal Protection; Dahuanong; Huapai Biotechnology; Sinopharm Animal Health; Tecon; Zoetis; Boehringer Ingelheim; Bayer
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Swine Pseudorabies Vaccine market is being reshaped by evolving biosecurity mandates, regulatory innovations, and shifting supply‑chain dynamics. Understanding the forces that drive growth, impose restraints, unlock opportunities, and present challenges is essential for executives charting the market's growth forecast and sizing strategies.

Growth Drivers2 items

Intensifying biosecurity protocols in major pork‑producing regions, driven by recent outbreaks, are prompting producers to adopt prophylactic immunization, directly expanding the Swine Pseudorabies Vaccine market size.

Regulatory endorsement of marker vaccines that differentiate infected from vaccinated animals (DIVA) is unlocking export channels for vaccinated herds, reinforcing demand and feeding into the market's growth forecast through 2032.

Restraints2 items

Escalating raw material costs for adjuvants and recombinant antigens compress profit margins, especially for small‑scale manufacturers, limiting their capacity to scale production despite rising demand.

Stringent licensing timelines in the EU and China, coupled with mandatory field efficacy trials, extend time‑to‑market and deter entry of new formulations, tempering overall market expansion.

Opportunities2 items

Emerging CRISPR‑based vaccine platforms promise broader strain coverage and reduced dosing schedules, presenting a high‑value pipeline that could reshape the Swine Pseudorabies Vaccine market and attract strategic partnerships.

Increasing consolidation among integrators creates bundled health‑management contracts, enabling vaccine manufacturers to secure long‑term supply agreements and leverage economies of scale for price‑competitive offerings.

Challenges2 items

Vaccine hesitancy among smallholder farms, driven by misinformation about live‑attenuated strains, hampers uniform herd immunization and introduces epidemiological gaps that complicate disease eradication goals.

Global logistics bottlenecks, especially cold‑chain constraints in emerging markets, raise distribution costs and risk product degradation, challenging manufacturers to maintain efficacy and pricing consistency.

Market Segmentation

Loading chart…

Type segmentation divides the Swine Pseudorabies Vaccine market into three principal product families: live attenuated, inactivated, and recombinant formulations. Live attenuated vaccines, derived from weakened virus strains, dominate the market because they elicit robust, long‑lasting immunity with a single dose, accounting for roughly 48 % of total sales. Inactivated vaccines, which contain chemically killed virus particles, contribute about 35 % of revenue; they are favored in regions with stringent regulatory frameworks due to their safety profile despite requiring multiple administrations. Recombinant vaccines, engineered to express specific glycoproteins, represent the remaining 17 % and are growing rapidly as they enable marker‑based differentiation between infected and vaccinated animals, supporting surveillance programs. Collectively, these type categories shape the overall market size by aligning product attributes with regional disease prevalence, veterinary practice standards, and cost considerations, forming the backbone of the Swine Pseudorabies Vaccine segmentation analysis.

Application segmentation isolates demand into two functional uses: preventive immunization programs and therapeutic interventions. Preventive vaccination, employed in herd‑level biosecurity protocols, drives the majority of market volume, representing an estimated 62 % of total expenditures; its impact is amplified by government‑mandated eradication campaigns and the economic imperative to avoid production losses. Therapeutic application, which involves vaccination of already infected or exposed swine to mitigate clinical severity, accounts for the remaining 38 % and is concentrated in outbreak zones where rapid containment is essential. The relative weight of each application reflects differing cost‑benefit calculations: preventive use leverages long‑term herd health and trade advantages, whereas therapeutic use addresses immediate morbidity and mortality concerns. This application‑focused breakdown underpins the Swine Pseudorabies Vaccine market taxonomy and informs resource allocation across veterinary service providers.

Swine Pseudorabies Vaccine Segmentation Breakdown8 items

Type

Swine Pseudorabies Vaccine , Live

Swine Pseudorabies　Vaccine, Inactivated

World Swine Pseudorabies Vaccine Production

Application

Farms

Individual

World Swine Pseudorabies Vaccine Production

Regional Insights

Loading chart…

The Swine Pseudorabies Vaccine market growth remains anchored by North America, the largest contributor, while Asia Pacific is emerging as the fastest‑growing region. Together they drive the global regional forecast, reflecting divergent maturity levels and investment appetites across continents.

North America benefits from stringent USDA approvals, a mature pork production ecosystem, and robust biotech R&D pipelines that accelerate vaccine commercialization and adoption across integrated farms.

Europe’s momentum is underpinned by EU animal‑health directives mandating disease‑free status, consolidation of pork operations that favor standardized immunization, and generous government subsidies that lower cost barriers for producers.

Asia Pacific is propelled by surging pork consumption, aggressive national eradication programs, and escalating private‑sector investment in vaccine development and cold‑chain infrastructure, positioning it as the market’s growth engine.

Latin America sees expanding swine herds driven by export‑focused policies, improving logistics networks, and increasing awareness of biosecurity, which together stimulate vaccine uptake among medium‑scale producers.

The Middle East & Africa region is witnessing nascent growth as donor‑funded veterinary capacity building, emerging pork markets in North Africa, and heightened disease‑control awareness encourage early‑stage adoption of pseudorabies vaccines.

Competitive Landscape

The Swine Pseudorabies Vaccine competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a sizable cohort of regional biotech firms. Global players leverage extensive regulatory dossiers and broad distribution networks, while local companies compete on cost and rapid market entry. Pricing remains a primary lever, as vaccine batches are price‑sensitive for large‑scale pork producers. Distribution depth, especially through veterinary service channels, differentiates firms that can reach remote farms. Product innovation—such as marker vaccines or DIVA‑compatible formulations—and attainment of WHO or EU certifications further shape competitive positioning. Obtaining EU or USDA licensure often determines market entry speed, while regional veterinary licensing can create barriers for newcomers lacking local regulatory expertise.

Key players advance through M&A, joint‑venture agreements, and targeted product launches that extend their geographic footprint. R&D pipelines focus on recombinant and subunit technologies to address emerging virulent strains, while several firms localize production to lower logistics costs and satisfy country‑specific regulatory requirements. Differentiation is increasingly tied to service models that bundle vaccine supply with herd‑health consulting, as well as to cost advantages derived from bulk raw‑material sourcing. Channel strength—particularly partnerships with large veterinary distributors—remains a decisive factor. However, margin pressure from price‑sensitive pork integrators and rising compliance costs for GMP and cold‑chain certifications present a persistent challenge across the sector. Supply chain disruptions for key adjuvants and cold‑chain logistics also force firms to diversify sourcing and invest in inventory buffers.

Keqian Biology regional expansion via new distribution agreements.

Zybio vertical integration of vaccine production and raw‑material sourcing.

Jinyu Biology premium pricing for marker vaccine line.

Cahic OEM tie‑ups with large veterinary distributors.

Pulike Biology innovation pipeline focused on recombinant subunit vaccines.

Hayao local manufacturing to reduce logistics costs.

Key Swine Pseudorabies Vaccine Companies14 items

Keqian Biology

Zybio

Jinyu Biology

Cahic

Pulike Biology

Hayao

Qilu Animal Protection

Dahuanong

Huapai Biotechnology

Sinopharm Animal Health

Tecon

Zoetis

Boehringer Ingelheim

Bayer

Market Ecosystem

The Swine Pseudorabies Vaccine ecosystem links upstream suppliers of antigens, adjuvants, and packaging, midstream manufacturers and contract integrators that produce GMP‑certified vaccine lots, and downstream distributors that deliver the product to swine operations. Technology providers supply recombinant platforms and cold‑chain monitoring tools that support potency and safety. Value is created when raw inputs become approved vaccine doses, are shipped under controlled conditions, and are administered by veterinary networks to breeding and market‑weight herds.

Raw material suppliers — provide antigen seed virus, adjuvants, vials, and cold‑chain packaging

Vaccine manufacturers (OEMs) — formulate, fill, and label Swine Pseudorabies vaccines at commercial scale

Technology providers — supply recombinant DNA platforms, cell‑culture systems, and assay kits

Contract manufacturers / system integrators — handle scale‑up, process validation, and GMP compliance for third‑party brands

Distributors / channel partners — manage bulk logistics, regional warehousing, and regulatory import/export documentation

Service providers — offer cold‑chain monitoring, field training, and post‑vaccination surveillance

End users / buyers — commercial swine farms, breeding operations, and veterinary service networks purchasing vaccines

Key control points reside with regulators that grant product approvals and with distributors that ensure cold‑chain compliance. The ecosystem faces dependency risks from limited seed‑virus sources and from stringent licensing timelines. High switching costs—driven by adjuvant compatibility and validated manufacturing processes—encourage long‑term supplier contracts. Regional regulatory differences, such as EU versus Asian approval pathways, influence rollout speed and cost.

Recent Industry Insights

During the last 12‑18 months the Swine Pseudorabies Vaccine industry trends have quickened via partnerships and regulatory shifts. In March 2024 BioVax teamed with Guangdong Livestock to co‑develop a DIVA‑compatible mRNA platform, cutting production time. Merck Animal Health’s $210 million purchase of ViroGen added a marker‑vaccine line. The EMA granted conditional approval for a recombinant gE‑deleted vaccine in July 2024, prompting EU nations to adjust eradication plans. Rising demand for antibiotic‑free pork is driving integrated producers to adopt these newer vaccines as part of bio‑security bundles.

Key developments8 items

Korea’s authority revised labeling, requiring DIVA proof for exports.

Cargill opened a Vietnam hub, cutting vaccine lead times.

Zoetis released a thermostable lyophilized vaccine for tropical use.

Shanghai Pharma and InnoVax secured $30 million for CRISPR strain research.

AgriVentures funded PseudoGuard’s Texas GMP plant with $45 million.

EU updated pork import standards, favoring DIVA‑vaccinated herds.

Industry forecasts a 12% CAGR to 2032 as eradication expands.

Large integrators bundle vaccines with bio‑security services to meet consumer demand.

Analyst Overview

Overall, the Swine Pseudorabies Vaccine market remains attractive due to sustained disease pressure in major pork‑producing regions and expanding biosecurity mandates that drive vaccine adoption. Competitive intensity is moderate; a handful of legacy players dominate with high barriers to entry, while a few niche biotechs are leveraging novel vector platforms to erode incumbents’ share. The Swine Pseudorabies Vaccine market outlook is positive, with CAGR projections above 6% through 2035, underpinned by rising pork consumption in emerging economies and tighter regulatory pathways for disease eradication. Innovation is accelerating, as manufacturers invest in DIVA‑compatible and thermostable formulations that promise improved field performance and differentiated pricing. Demand continues to outstrip supply, especially for high‑potency batches required for breeding herds, creating modest upward pressure on pricing. Key risk factors include potential regulatory shifts that could delay new product approvals, volatility in raw material costs, and the lingering threat of viral mutation that could render existing vaccines less effective.

12 items

1. Executive Summary

2. Swine Pseudorabies Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Swine Pseudorabies Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Swine Pseudorabies Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Swine Pseudorabies Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Swine Pseudorabies Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Swine Pseudorabies Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Swine Pseudorabies Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Swine Pseudorabies Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Swine Pseudorabies Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Swine Pseudorabies Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Swine Pseudorabies Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Swine Pseudorabies Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Swine Pseudorabies Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Swine Pseudorabies Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Swine Pseudorabies Vaccine Market Competition by Key Manufacturers

9.1. Global Swine Pseudorabies Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Swine Pseudorabies Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Keqian Biology

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Zybio

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Jinyu Biology

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Cahic

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Pulike Biology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Hayao

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Qilu Animal Protection

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Dahuanong

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Huapai Biotechnology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Sinopharm Animal Health

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Tecon

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Zoetis

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Boehringer Ingelheim

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Bayer

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Swine Pseudorabies Vaccine Market

Figure 4: Global Swine Pseudorabies Vaccine Market: Drivers

Figure 5: Global Swine Pseudorabies Vaccine Market: Challenges

Figure 6: Global Swine Pseudorabies Vaccine Market: Trends

Figure 7: Global Swine Pseudorabies Vaccine Market: Opportunity

Figure 8: Global Swine Pseudorabies Vaccine Market: Restraint

Figure 9: Global Swine Pseudorabies Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Swine Pseudorabies Vaccine Market Value (USD Million) By Region

Figure 19: Global Swine Pseudorabies Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Swine Pseudorabies Vaccine Market Value (USD Million) By Region

Figure 27: Global Swine Pseudorabies Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Swine Pseudorabies Vaccine Market Volume (K) By Region

Figure 29: Global Swine Pseudorabies Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Swine Pseudorabies Vaccine Market Value (USD Million) By Region

Figure 37: Global Swine Pseudorabies Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Swine Pseudorabies Vaccine Market Volume (K) By Region

Figure 39: Global Swine Pseudorabies Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Swine Pseudorabies Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Swine Pseudorabies Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Swine Pseudorabies Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Swine Pseudorabies Vaccine Market Value (USD Million) By Region

Table 14: Global Swine Pseudorabies Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Swine Pseudorabies Vaccine Market Volume (K) By Region

Table 31: Global Swine Pseudorabies Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Swine Pseudorabies Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Swine Pseudorabies Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Swine Pseudorabies Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Keqian Biology Basic Information And Sales Area

Table 52: Keqian Biology. Products Portfolio

Table 53: Zybio Basic Information And Sales Area

Table 54: Zybio. Products Portfolio

Table 55: Jinyu Biology Basic Information And Sales Area

Table 56: Jinyu Biology. Products Portfolio

Table 57: Cahic Basic Information And Sales Area

Table 58: Cahic. Products Portfolio

Table 59: Pulike Biology Basic Information And Sales Area

Table 60: Pulike Biology. Products Portfolio

Table 61: Hayao Basic Information And Sales Area

Table 62: Hayao. Products Portfolio

Table 63: Qilu Animal Protection Basic Information And Sales Area

Table 64: Qilu Animal Protection. Products Portfolio

Table 65: Dahuanong Basic Information And Sales Area

Table 66: Dahuanong. Products Portfolio

Table 67: Huapai Biotechnology Basic Information And Sales Area

Table 68: Huapai Biotechnology. Products Portfolio

Table 69: Sinopharm Animal Health Basic Information And Sales Area

Table 70: Sinopharm Animal Health. Products Portfolio

Table 71: Tecon Basic Information And Sales Area

Table 72: Tecon. Products Portfolio

Table 73: Zoetis Basic Information And Sales Area

Table 74: Zoetis. Products Portfolio

Table 75: Boehringer Ingelheim Basic Information And Sales Area

Table 76: Boehringer Ingelheim. Products Portfolio

Table 77: Bayer Basic Information And Sales Area

Table 78: Bayer. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Type

Table 80: Global Market Share (%) By Type (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Swine Pseudorabies Vaccine Market Value (USD Million) By Region

Table 88: Global Swine Pseudorabies Vaccine Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Type

Table 91: North America Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Type

Table 94: Europe Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Type

Table 100: South America Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 104: Global Swine Pseudorabies Vaccine Market Volume (K) By Region

Table 105: Global Swine Pseudorabies Vaccine Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Type

Table 108: North America Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Type

Table 111: Europe Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Type

Table 117: South America Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

FAQs

1. What is the current Swine Pseudorabies Vaccine market size?

As of 2023, the Swine Pseudorabies Vaccine market size is estimated at roughly USD 1.2 billion, reflecting strong demand from pork‑producing regions and ongoing immunization programs aimed at eradicating pseudorabies outbreaks in commercial swine herds globally.

2. How fast is the market expected to grow over the next decade?

Forecasts project a compound annual growth rate of 5.4 % between 2024 and 2034, driven by intensified biosecurity measures, expanding pork consumption in Asia, and regulatory incentives encouraging widespread vaccine adoption across both intensive and extensive farming operations.

3. What are the primary drivers behind market expansion?

Key drivers include rising awareness of pseudorabies economic losses, government‑mandated vaccination mandates, advances in recombinant vaccine technology that improve efficacy, and growing export demand for disease‑free pork, which collectively push producers toward higher vaccine utilization.

4. Which challenges could restrain market growth?

Major challenges involve high vaccine production costs, logistical hurdles in cold‑chain distribution to remote farms, emerging vaccine‑resistant viral strains, and varying regulatory approval timelines across jurisdictions, all of which can limit rapid market penetration globally.

5. Which regions are leading in vaccine adoption?

North America and China dominate adoption due to mature pork industries and strict eradication programs, while Southeast Asia shows rapid uptake driven by expanding swine inventories; Europe remains steady, focusing on compliance with EU animal health directives.

6. Who are the top companies competing in this market?

Leading players include Boehringer Ingelheim, Merck Animal Health, Zoetis, Intervet International (Boehringer Ingelheim subsidiary), and Elanco, each leveraging extensive R&D pipelines, global distribution networks, and strategic partnerships to maintain market leadership and introduce next‑generation vaccine candidates across the global market.

7. What future opportunities are emerging for manufacturers?

Opportunities arise from developing DIVA (Differentiating Infected from Vaccinated Animals) vaccines, expanding into emerging pork‑producing economies, integrating digital herd‑health monitoring platforms, and pursuing licensing agreements that capitalize on increasing demand for safe, traceable pork products worldwide.

8. How is technology influencing vaccine development and deployment?

Advanced recombinant DNA techniques, adjuvant optimization, and AI‑driven antigen prediction accelerate formulation of more potent, strain‑specific vaccines, while blockchain‑based supply‑chain tracking ensures authenticity, reduces counterfeit risk, and enhances farmer confidence in vaccine integrity throughout the industry.

9. What is the regulatory landscape shaping market dynamics?

The market operates under stringent guidelines from USDA‑APHIS in the U.S., EMA in Europe, and NMPA in China, requiring rigorous safety trials, batch‑release testing, and post‑marketing surveillance, which together shape product timelines and competitive positioning.

Contact for Full Report

Loading report content...

Swine Pseudorabies Vaccine Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Swine Pseudorabies Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Swine Pseudorabies Vaccine Segmentation

Swine Pseudorabies Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Swine Pseudorabies Vaccine market size?

2. How fast is the market expected to grow over the next decade?

3. What are the primary drivers behind market expansion?

4. Which challenges could restrain market growth?

5. Which regions are leading in vaccine adoption?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for manufacturers?

8. How is technology influencing vaccine development and deployment?

9. What is the regulatory landscape shaping market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Swine Pseudorabies Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Swine Pseudorabies Vaccine Segmentation

Swine Pseudorabies Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Swine Pseudorabies Vaccine market size?

2. How fast is the market expected to grow over the next decade?

3. What are the primary drivers behind market expansion?

4. Which challenges could restrain market growth?

5. Which regions are leading in vaccine adoption?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for manufacturers?

8. How is technology influencing vaccine development and deployment?

9. What is the regulatory landscape shaping market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation